Researchers have discovered that the risk of death from breast cancer is twice as high for patients with high heterogeneity of the estrogen receptor within the same tumor as compared to patients with low heterogeneity. The study shows that the higher risk of death is independent of other known tumor markers and also holds true for Luminal A breast cancer.